CRISPR Therapeutics AG

NASDAQ:CRSPUnited States

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Contact Information

Headquarters

Baarerstrasse 14ZUG, ZUG, Switzerland 6300

Phone

---

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Samarth Kulkarni

Chief Financial Officer

Raju Prasad

Chief Operating Officer

Julianne Bruno

General Counsel, Secretary

James Kasinger

Chief Medical Officer

Naimish Patel